Although the treatment of metastatic pancreatic adenocarcinoma across Europe generally follows the ESMO guideline, there are substantial geographic variations in treatment patterns used as first-line therapies.
Browsing: Disease Area > Pancreatic
Adjuvant FOLFIRINOX chemotherapy has become the standard of care for pancrearic cancer patients following the release of data from the Phase III PRODIGE 24/CCTG PA.6 trial.
Results of a randomized clinical trial, presented at ASCO 2018, highlight the benefit of preoperative chemoradiotherapy for patients with pancreatic cancer that can be treated with surgery.
The objective of this study is to identify the effect of diabetes mellitus on survival of patients with pancreatic cancer and to determine whether pancreatic cancer and its treatment affect glycemic control.
The use of a new smartphone app could detect early signs of pancreatic cancer, potentially helping to diagnose pancreatic cancer whilst tumors are still treatable.
In this editorial find out about the promises and limitations of gemcitabine monotherapy as an adjuvant chemotherapy in pancreatic adenocarcinoma.
Researchers have identified a panel of biomarkers in serum samples that could accurately detect the early stages of pancreatic cancer.
Listen to our exclusive interview with Philip A Philip to find out about novel agents and strategies on the horizon for pancreatic cancer.
A group of researchers may have improved the efficacy of cancer immunotherapy by blocking two proteins that regulate the growth of tumor blood vessels.
Lydia Makaroff of the European Cancer Patient Coalition (ECPC, Brussels, Belgium) speaks with Oncology Central about the goals and upcoming projects for the ECPC in 2017.